- Home
- UBSI vs BBIO Comparison
UBSI vs BBIO Comparison
Compare UBSI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- BBIO
- Stock Information
- Founded
- UBSI 1982
- BBIO 2015
- Country
- UBSI United States
- BBIO United States
- Employees
- UBSI N/A
- BBIO N/A
- Industry
- UBSI Major Banks
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- UBSI Finance
- BBIO Health Care
- Exchange
- UBSI Nasdaq
- BBIO Nasdaq
- Market Cap
- UBSI 4.9B
- BBIO 5.6B
- IPO Year
- UBSI N/A
- BBIO 2019
- Fundamental
- Price
- UBSI $38.53
- BBIO $33.79
- Analyst Decision
- UBSI Hold
- BBIO Strong Buy
- Analyst Count
- UBSI 3
- BBIO 13
- Target Price
- UBSI $40.00
- BBIO $48.33
- AVG Volume (30 Days)
- UBSI 596.9K
- BBIO 2.6M
- Earning Date
- UBSI 01-27-2025
- BBIO 02-20-2025
- Dividend Yield
- UBSI 3.84%
- BBIO N/A
- EPS Growth
- UBSI N/A
- BBIO N/A
- EPS
- UBSI 2.65
- BBIO N/A
- Revenue
- UBSI $1,010,865,000.00
- BBIO $217,765,000.00
- Revenue This Year
- UBSI N/A
- BBIO $2,309.33
- Revenue Next Year
- UBSI $11.72
- BBIO N/A
- P/E Ratio
- UBSI $14.54
- BBIO N/A
- Revenue Growth
- UBSI N/A
- BBIO 2209.77
- 52 Week Low
- UBSI $30.68
- BBIO $21.62
- 52 Week High
- UBSI $44.43
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- UBSI 51.63
- BBIO 68.27
- Support Level
- UBSI $37.77
- BBIO $33.73
- Resistance Level
- UBSI $39.09
- BBIO $36.24
- Average True Range (ATR)
- UBSI 0.92
- BBIO 1.55
- MACD
- UBSI 0.24
- BBIO 0.60
- Stochastic Oscillator
- UBSI 85.26
- BBIO 72.81
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in two segments: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services; and Mortgage banking, which offers and acquires home mortgages through an indirectly owned subsidiary. Nearly all revenue comes from the community banking segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.